English High Court refers Truvada SPC case to CJEU

The English High Court has referred a supplementary protection certificate (SPC) dispute over Truvada (emtricitabine/tenofovir) to Europe’s highest court, the Court of Justice of the European Union (CJEU).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

CJEU clarifies ‘basic patent’ meaning in SPC dispute

25 July 2018 Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.

Big Pharma

French court knocks out Gilead Truvada SPC

4 June 2018 The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.

Big Pharma

AG opines on ‘thorny issue’ in Truvada SPC clash

25 April 2018 Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

English High Court refers Truvada SPC case to CJEU

More on this story

Editor's picks

Editor's picks

More features